DR. SEAN MICHAEL WARSCH M.D. NPI 1750608246

NPI Details

DR. Sean Michael Warsch, M.D. is a hematology and oncology internal medicine in Asheville, NC with 16 years of experience. The provider is an internist doctor of osteopathy that specializes in the treatment of the combination of hematology and oncology disorders. A doctor of osteopathy that is board eligible/certified by the American Osteopathic Board of Internal Medicine WAS able to obtain a Certificate of Special Qualifications in the field of Hematology and Oncology. The Certificate is NO longer offered. DR. Sean Michael Warsch, M.D. NPI is 1750608246. The provider is registered as an individual entity type.

The NPPES NPI record indicates the provider is a male.

Education
Medical School: UNIVERSITY OF MIAMI, LM MILLER SCHOOL OF MEDICINE
Graduation Year:2010

The provider's business location address is:

551 BREVARD RD
ASHEVILLE, NC
ZIP 28806-316
Phone: (828) 212-7021
Fax: (828) 232-8218

The NPI 1750608246 is registered in the Medicare Provider, Enrollment, Chain and Ownership System (PECOS). The provider is legally eligible to order and refer Part B (Clinical Laboratory and Imaging), Durable Medical Equipment, Part A Home Health Agency (HHA), Power Mobility Devices.

The following top HCPCS codes were publicly reported for this provider under the Medicare program for the year 2016. The reported codes are based on the top codes for each available Medicare specialty, excluding evaluation and management codes.

• Injection, pembrolizumab, 1 mg (HCPCS:J9271)
• Injection, aprepitant, 1 mg (HCPCS:J0185)
• Injection, denosumab, 1 mg (HCPCS:J0897)
• Injection, daratumumab, 10 mg and hyaluronidase-fihj (HCPCS:J9144)
• Injection, ferumoxytol, for treatment of iron deficiency anemia, 1 mg (non-esrd use) (HCPCS:Q0138)
• Injection, oxaliplatin, 0.5 mg (HCPCS:J9263)
• Injection, epoetin alfa, (for non-esrd use), 1000 units (HCPCS:J0885)
• Injection, paclitaxel, 1 mg (HCPCS:J9267)
• Injection, bevacizumab-bvzr, biosimilar, (zirabev), 10 mg (HCPCS:Q5118)
• Injection, dexamethasone sodium phosphate, 1 mg (HCPCS:J1100)
• Injection, rituximab-pvvr, biosimilar, (ruxience), 10 mg (HCPCS:Q5119)
• Complete blood cell count (red cells, white blood cell, platelets), automated test and automated differential white blood cell count (HCPCS:85025)
• Injection, palonosetron hcl, 25 mcg (HCPCS:J2469)
• Insertion of needle into vein for collection of blood sample (HCPCS:36415)
• Injection, immune globulin, (gammagard liquid), non-lyophilized, (e.g., liquid), 500 mg (HCPCS:J1569)
• Injection, leucovorin calcium, per 50 mg (HCPCS:J0640)
• Administration of chemotherapy into vein, 1 hour or less (HCPCS:96413)
• Injection, ondansetron hydrochloride, per 1 mg (HCPCS:J2405)
• Established patient office or other outpatient visit, 30-39 minutes (HCPCS:99214)
• Injection, fluorouracil, 500 mg (HCPCS:J9190)
• Injection of additional new drug or substance into vein (HCPCS:96375)
• Injection, carboplatin, 50 mg (HCPCS:J9045)
• Injection of drug or substance under skin or into muscle (HCPCS:96372)
• Established patient office or other outpatient visit, 20-29 minutes (HCPCS:99213)
• Established patient office or other outpatient visit, 40-54 minutes (HCPCS:99215)
• Infusion into a vein for therapy, prevention, or diagnosis, additional sequential infusion, 1 hour or less (HCPCS:96367)
• Injection, diphenhydramine hcl, up to 50 mg (HCPCS:J1200)
• Injection, magnesium sulfate, per 500 mg (HCPCS:J3475)
• Follow-up hospital inpatient care per day, typically 25 minutes (HCPCS:99232)
• Injection, zoledronic acid, 1 mg (HCPCS:J3489)
• Administration of additional new drug or substance into vein, 1 hour or less (HCPCS:96417)
• Infusion, normal saline solution , 1000 cc (HCPCS:J7030)
• Infusion into a vein for therapy, prevention, or diagnosis, 1 hour or less (HCPCS:96365)
• Administration of non-hormonal anti-neoplastic chemotherapy under skin or into muscle (HCPCS:96401)
• Follow-up hospital inpatient care per day, typically 35 minutes (HCPCS:99233)
• Administration of chemotherapy into vein, each additional hour (HCPCS:96415)
• New patient office or other outpatient visit, 45-59 minutes (HCPCS:99204)
• Leuprolide acetate (for depot suspension), 7.5 mg (HCPCS:J9217)
• Administration of additional new drug or substance into vein using push technique (HCPCS:96411)
• Irrigation of implanted venous access drug delivery device (HCPCS:96523)
• Infusion into a vein for hydration, 31-60 minutes (HCPCS:96360)
• Infusion into a vein for therapy, prevention, or diagnosis, each additional hour (HCPCS:96366)
• Initial hospital inpatient care per day, typically 70 minutes (HCPCS:99223)
• Administration of hormonal anti-neoplastic chemotherapy under skin or into muscle (HCPCS:96402)
• Infusion into a vein for hydration, each additional hour (HCPCS:96361)
• Urinalysis, manual test (HCPCS:81002)
• Chemotherapy administration, intravenous infusion technique; initiation of infusion in the office/clinic setting using office/clinic pump/supplies, with continuation of the infusion in the community setting (e.g., home, domiciliary, rest home or assisted l (HCPCS:G0498)
• Office or other outpatient visit for the evaluation and management of established patient that may not require presence of healthcare professional (HCPCS:99211)
• Principal care management services for a single high-risk disease, first 30 minutes of clinical staff time directed by health care professional, per calendar month (HCPCS:99426)
• Blood test, comprehensive group of blood chemicals (HCPCS:80053)
• New patient office or other outpatient visit, 60-74 minutes (HCPCS:99205)
• Injection of drug or substance into vein (HCPCS:96374)
• Infusion into a vein for therapy, prevention, or diagnosis concurrent with another infusion (HCPCS:96368)
• Drawing of blood for a medical problem (HCPCS:99195)
• Unclassified drugs (HCPCS:J3490)
• Administration of chemotherapy into vein using push technique (HCPCS:96409)
• Hospital discharge day management, more than 30 minutes (HCPCS:99239)
• Injection, vitamin b-12 cyanocobalamin, up to 1000 mcg (HCPCS:J3420)
• Injection, methylprednisolone sodium succinate, up to 40 mg (HCPCS:J2920)

The enumeration date for this NPI number is 4/23/2010 and was last updated on 12/29/2022.

Taxonomy Codes

The NPI record includes the healthcare provider taxonomy classification, state license number and state of licensure. The following information regarding the scope of practice of this provider is available: